Endo to buy generics maker Par Pharmaceutical for $8B

Posted online May 18, 2015 | 6:29 am

Endo International PLC has agreed to buy Par Pharmaceutical Holdings Inc. from private-equity firm TPG for about $8 billion in cash and stock, a deal that would help boost its generics business.

The combined company would have a generics business among the top five by U.S. sales, according to Endo.

Dow Jones Newswires reports Par has some 100 products, including oral solid and injectables. TPG took the company private in 2012 for about $1.9 billion.

Read more from Dow Jones Newswires.[[In-content Ad]]

Comments

No comments on this story |

Please log in to add your comment

TLC Properties loses Edgewood REIT management contract

Editors' Pick

From the Ground Up: Premier Truck Group sales and repair facility

Logistics company Premier Truck Group is building a new truck sales and repair facility in Strafford, using precast contract, metal framing, thermoplastic polyolefin roofing and standing-seam metal in its construction.

Most Read